Omalizumab
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Omalizumab: Bronchitis
One-Sentence Summary
Omalizumab is an anti-IgE monoclonal antibody that is currently marketed in Australia. The TxGNN model predicts it may be effective for bronchitis (score 1.0000). However, no published study directly supports omalizumab in bronchitis, so the evidence level is L5 (model prediction only), with 2 registered trials and 7 publications that are at best indirectly related.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Pharmacology data show that omalizumab targets immunoglobulin E (IgE, gene IGHE). By binding free IgE, it reduces activation of mast cells and basophils through the high-affinity IgE receptor (FcεRI), which is relevant to allergic airway inflammation.
The link to bronchitis is indirect. The supporting literature concerns allergic asthma and airway disease in people with asthma, not bronchitis itself. Any benefit would plausibly apply only to a subset of patients with an allergic, atopic or eosinophilic airway phenotype. The high model score should therefore be read as a hypothesis to test, not as evidence of efficacy.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT02049294 | Phase 2/3 | Completed | 11 | Placebo-controlled study of the steroid-sparing effect of omalizumab in persistent eosinophilic bronchitis. It was published as a study of severe asthma with persistent sputum eosinophilia, and omalizumab was possibly inadequate. Very small sample. |
| NCT02477332 | Phase 2 | Completed | 382 | Dose-finding study of QGE031 (a different anti-IgE agent) in chronic spontaneous urticaria. It does not address bronchitis and is listed for completeness only. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21121874 | 2011 | Cohort (pooled analysis) | Curr Med Res Opin | Safety and tolerability of omalizumab in children with allergic asthma. Not bronchitis-specific. |
| 16222080 | 2005 | Review | Clin Rev Allergy Immunol | Omalizumab reduces free IgE and FcεRI expression, decreasing airway inflammation in moderate-to-severe persistent asthma. |
| 30196731 | 2018 | Review | Expert Opin Pharmacother | Smoking-induced airway diseases, including chronic bronchitis, contribute to symptoms in adults with asthma. Treatment is uncertain because these patients are excluded from most trials. |
| 26466493 | 2015 | Review | Masui (Jpn J Anesthesiol) | Preoperative management of patients with bronchial asthma or chronic bronchitis. Mentions omalizumab as an option for severe allergic asthma. |
| 17663923 | 2007 | Review | Allergol Immunopathol | General update on monoclonal antibodies in paediatric prevention and treatment. Not bronchitis-specific. |
| 31478531 | 2019 | Case report | J Investig Allergol Clin Immunol | Rare case of plastic bronchitis following bronchial thermoplasty. No efficacy conclusion for omalizumab. |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 10109C | Omlyclo | Injection 150 mg in 1 mL single dose pre-filled syringe | Not available in the data compiled for this report |
Safety Considerations
Drug Interactions (8 interaction records in the data compiled for this report):
- Moderate: omacetaxine mepesuccinate
- Minor: zinc sulfate, zinc acetate, zinc gluconate, zinc chloride, Echinacea, vitamin E
No key warnings or contraindications are available in the compiled data. Please refer to the TGA-approved Product Information (PI) for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but no published study supports omalizumab in bronchitis. The one bronchitis-titled trial was tiny (11 participants) and was published as a severe asthma study in which omalizumab was possibly inadequate. The evidence level is therefore L5, and the mechanistic link is indirect.
To proceed, the following is needed:
- A bronchitis-specific controlled study, ideally in a defined allergic or eosinophilic phenotype
- Detailed mechanism of action data to support the proposed link
- Review of TGA Product Information for warnings and contraindications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.